Antigenics To Raise $10M In Private Placement
Antigenics has entered into definitive agreements to sell in a private placement of approximately 5 million shares of its common stock at a price of $2.00 per share.
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
Cardium has reported plans to develop a DNA-based orthobiologics product portfolio, based on research and development by Cardium’s Tissue Repair Company. It will initially focus on non-union bone